Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Dia Beta Labs is a biotechnology company dedicated to improving the lives of individuals with metabolic diseases. It operates from Ulster, where it has access to advanced facilities and a network of experts. The company's focus is on developing therapeutic agents to address the decline of pancreatic health in patients, with the goal of achieving more sustainable and effective weight loss than current options. Its discovery platform uses industry-standard methodologies and models to identify and advance lead molecules for animal research.

Keltic Pharma Therapeutics enhances drug discovery through innovative scientific research, resulting in a healthier future.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Lentitek is a cell and gene therapy company developing gene therapies and gene-modified cell therapies to broaden access to cures. It focuses on increasing the production yields of lentiviral vectors through its platform, using a novel promoter and proprietary production methods. The approach aims to deliver substantially higher yields, potentially reducing manufacturing costs and improving scalability for healthcare providers delivering gene therapies.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Founded in 2009, MedAnnex is a UK-based biotechnology company dedicated to developing first-in-class antibody therapies for treating cancers and autoimmune diseases. Its lead product, annexuzlimab, targets annexin-A1 to inhibit cancer cell growth and autoimmune condition development.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

Monument Therapeutics is a biotechnology company focused on developing drugs for treating serious diseases of the central nervous system. Its innovative approach employs proprietary digital biomarkers to reduce patient heterogeneity, enabling more targeted neuroscience drug development in areas with unmet medical needs.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Lucida Medical develops artificial intelligence–based healthcare technology to aid clinicians in the detection and diagnosis of cancer. Its platform analyzes imaging data from MRI and integrates imaging and multi-omics biomarkers and reporting tools to support cancer screening and diagnosis, with the aim of making detection more accurate, accessible, and faster while reducing costs. The company’s first product, Pi, is designed to assist in diagnosing prostate cancer using multiparametric or diffusion MRI and is a CE marked medical device.

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Laverock Therapeutics develops a gene silencing platform for creating programmable, allogeneic cell therapies.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

Plasticell is a biotechnology company focused on developing innovative therapeutic solutions through advanced cell culture and drug discovery platforms. By investigating the biochemical mechanisms that govern stem cell behavior, Plasticell aims to create regenerative small molecule drugs that support tissue development and repair. The company offers comprehensive support for researchers in cell biology by enabling the testing of numerous cell culture variables, thereby optimizing laboratory protocols for various outcomes. This approach facilitates the differentiation of cells and enhances processes such as gene transduction and protein production, ultimately contributing to the advancement of novel therapies in regenerative medicine.

NK:IO is a biotechnology company focused on developing natural killer cell-mediated immunotherapies for cancer. The company develops both cell therapies and small molecule therapeutics designed to target cancer and enhance the tumor-killing activity of natural killer cells.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

XR Therapeutics is a startup spun out of Newcastle University, offering healthcare services to support individuals with anxiety and phobias. It combines cognitive behavioral techniques with virtual reality simulations, recreating tailored scenarios in a controlled environment for effective treatment.

InsideOut specializes in mental health care and well-being support and is based in London. The company develops a health therapy platform delivered through an online application that uses an intelligent matching system to connect users with therapists, with the aim of breaking down social stigma and facilitating ongoing mental health care and positive well-being.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.

Calla Lily Clinical Care is a women's health company focused on developing innovative drug delivery systems. Their proprietary platform, Callavid®, enables intravaginal drug delivery for various indications, including fertility and pregnancy support, prevention of recurrent bacterial vaginosis, hormone replacement therapy for menopause, and biomarker-based diagnostic tests.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

Syndi is a digital health support recommendation platform that utilizes machine learning and digital phenotyping, with a primary focus on mental health. The company develops technology-driven solutions aimed at enhancing individuals' health by providing effective and accessible support. Syndi's platform employs passive smartphone data collection to gather moment-to-moment information about users, allowing it to deliver personalized and immediate care. This innovative approach not only facilitates connections between patients and healthcare providers but also measures the effectiveness of applications and digital services in treating invisible disabilities. Through its commitment to leveraging technology and research, Syndi seeks to improve healthcare outcomes for its users.

Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Aten Therapeutics specializes in developing novel therapeutic antibodies targeting fundamental control pathways associated with major diseases. Their experienced management team aims to extend and improve patients' lives by creating powerful new treatments.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Neumind develops mobile solutions for people with neurological conditions and injuries. Its app Alfred provides practical and therapeutic support for patients and their caregivers, helping individuals live more independently and maintain function. The platform uses smartphone technology to support key cognitive functions, stimulate neural pathways, and establish behaviours and strategies grounded in neurorehabilitation and cognitive-behavioral science. Founded in 2019 and based in Great Shelford, Cambridge, Neumind aims to enable people affected by brain injuries, dementia, and related conditions to lead more independent, functional lives.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

Founded in 2016, Five Alarm Bio is a biotechnology company based in Cambridge, UK. It focuses on drug discovery to develop anti-aging therapies using a small molecule approach, aiming to enhance the body's defenses against aging-related damage and diseases.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Sixfold Bioscience Inc. is a London-based company founded in 2018 that specializes in the development of innovative drug delivery techniques aimed at treating cancer patients. The company focuses on engineering programmable oligonucleotide delivery systems that are designed to deliver RNA specifically to diseased cells. This targeted approach enhances the efficacy of treatments while minimizing side effects, positioning Sixfold Bioscience at the forefront of advancements in cancer therapy.

Calla Lily Clinical Care is a women's health company focused on developing innovative drug delivery systems. Their proprietary platform, Callavid®, enables intravaginal drug delivery for various indications, including fertility and pregnancy support, prevention of recurrent bacterial vaginosis, hormone replacement therapy for menopause, and biomarker-based diagnostic tests.

Founded in 2018 and based in Sheffield, UK, Rinri Therapeutics is a biotechnology company dedicated to developing regenerative stem cell-based therapies for treating hearing loss. Its innovative therapy aims to replace damaged sensory cells of the inner ear, restoring patients' hearing.

Glamorous AI develops an artificial intelligence driven drug discovery platform that accelerates pharmaceutical research by leveraging prior experimental results to identify and optimize chemical scaffolds, predict activities, and screen ultra-large chemical libraries. The platform addresses low-data, sparse, and noisy datasets, enabling the discovery of novel compounds and potential therapeutics.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Founded in 2015 and based in Cambridge, UK, Camallergy is a biopharmaceutical company focused on developing innovative treatments for food allergies. Its lead product is an oral immunotherapy designed to provide significant protection against peanut allergy within just three months.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Lumino is focused on enhancing mental health outcomes through the development of digital therapeutic programs. These programs specifically address various mental health concerns and incorporate techniques such as cognitive behavioral therapy (CBT) to help individuals manage their symptoms effectively. Supported by Innovate UK and the Oxford Academic Health Science Network, Lumino aims to leverage digital technology to deliver scalable mental health services, ultimately promoting healthier and happier lives for users.

Ablatus Therapeutics Limited is a medical device company based in Norwich, United Kingdom, focused on developing and commercializing innovative tissue ablation technology for the treatment of challenging and often inoperable solid cancer tumors. Founded in 2015, the company has created a proprietary Bimodal Electric Tissue Ablation system that utilizes radiofrequency (RF) energy to generate localized heating and effectively destroy target tissues. This advanced approach provides clinicians with new options for treating tumors, aiming to improve patient outcomes in oncology care.

DIOSynVax is a vaccine antigen design company focused on enhancing vaccine development through innovative technology. The company specializes in digitally designing, immune-optimized selecting, and synthesizing vaccines to improve protection against both emerging and re-emerging pathogens, including influenza, COVID-19, and viral hemorrhagic fevers. By leveraging its advanced technology, DIOSynVax aims to expedite the vaccine development process, ultimately enabling healthcare providers to treat patients more effectively and facilitate quicker recovery from various diseases. Through its efforts, DIOSynVax seeks to make significant advancements in public health by addressing the challenges posed by existing and future viruses.

Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Ampersand Health is focused on developing digital therapeutics for individuals with long-term inflammatory conditions. Based in London and incorporated in 2014, the company offers a comprehensive digital platform that includes the Ampersand Healthsuite, a management tool designed for patients, and Healthsuite for Clinicians, which supports clinician-led, patient-centered self-management. The platform utilizes behavioral science to deliver personalized therapy, featuring expert-led courses, self-management tracking, and clinical messaging. Ampersand Health aims to enhance patients' mental health and quality of life while also providing significant cost savings for healthcare providers by reducing overall healthcare utilization.

Kuano Ltd is a London-based company that specializes in providing quantum and artificial intelligence solutions for molecular design, particularly in the fields of drug discovery and development. Founded in 2020, Kuano has developed a unique discovery platform that integrates quantum simulation with AI-led chemistry, enabling the design of effective inhibitors by analyzing the mechanisms of target enzymes. This innovative approach allows for faster and more efficient development of drug candidates, enhancing the quality of new pharmaceuticals while simultaneously reducing the time required for discovery. The company's solutions are applicable across various sectors, including pharmaceuticals, crop protection, and industrial chemistry.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Lunac Therapeutics develops advanced oral anticoagulant medicines designed to prevent and treat life-threatening thrombotic events. The treatments seek to balance efficacy with safety by minimizing bleeding risk while preserving therapeutic effect, enabling clinicians to manage high-risk patients with safer dosing strategies.

Ixaka is a UK-based biotechnology company focused on developing advanced cell-based therapeutics to treat serious diseases. Its proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and modifying them within the body to improve their action, with potential applications across oncology, cardiovascular, neurological, ocular diseases, and genetic disorders.

Ampersand Health is focused on developing digital therapeutics for individuals with long-term inflammatory conditions. Based in London and incorporated in 2014, the company offers a comprehensive digital platform that includes the Ampersand Healthsuite, a management tool designed for patients, and Healthsuite for Clinicians, which supports clinician-led, patient-centered self-management. The platform utilizes behavioral science to deliver personalized therapy, featuring expert-led courses, self-management tracking, and clinical messaging. Ampersand Health aims to enhance patients' mental health and quality of life while also providing significant cost savings for healthcare providers by reducing overall healthcare utilization.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Nanna Therapeutics Limited, established in 2012 and headquartered in Cambridge, UK, is a biotechnology company focused on developing drugs for age-related diseases such as mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. As of April 2020, the company operates as a subsidiary of Astellas Pharma Europe Ltd. Nanna Therapeutics employs a unique approach by targeting fundamental cellular processes to create innovative treatments for these conditions, with a particular emphasis on mitochondria, the energy source in every cell. The company's proprietary drug discovery platform, TIME (Totally Integrated Medicines Engine), combines advanced technologies like microfluidics and artificial intelligence to accelerate drug development and disrupt traditional methods of creating new medicines.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Orbit Discovery is a biotechnology company specializing in peptide display technology to identify potential peptide drugs for chronic diseases. Its proprietary Orbit platform uses small beads linked with randomized peptide sequences to DNA, enabling screening tools for various disease types. The company focuses on establishing collaborative research platforms and internal drug discovery programs.

Founded in 2015, SageTech Medical develops innovative anesthetic technology for human and veterinary healthcare providers. Its patented process captures, extracts, and purifies inhalational anaesthetic agents, reducing costs and environmental pollution. The company offers solutions ranging from industrial-scale bulk capture to integrated recycling systems within anaesthetic machines.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

BIOS Health is a pioneering company focused on developing neural digital therapies by harnessing data-driven insights from the human nervous system. Co-founded by researchers from Cambridge University, the firm aims to revolutionize precision medicine through the identification of neural biomarkers that link nerve activity to various medical conditions. BIOS's innovative approach holds promise for treating chronic diseases such as hypertension, diabetes, rheumatoid arthritis, and neurodegenerative disorders like Parkinson's and Alzheimer's. The company's expertise encompasses a diverse range of fields, including neuroscience, machine learning, software engineering, and biotechnology, allowing it to create advanced solutions for improving the quality of life for individuals suffering from these conditions. Additionally, BIOS is engaged in developing prosthetic connectors that standardize the interface between bionic devices and the body's nervous and soft-tissue systems, enabling enhanced control and feedback for patients with prosthetics.

Medherant is a clinical-stage company focused on transdermal drug delivery for pain and central nervous system conditions. Its TEPI Patch uses an adhesive technology designed to enable higher drug loading, controlled release, and compatibility with a wide range of drug types, addressing limitations of conventional patches and reducing issues seen with creams and gels. The platform emphasizes water resistance and efficient drug delivery to improve patient comfort and therapeutic effectiveness. Medherant originated from academic work at the University of Warwick led by Professor David Haddleton and was founded in 2014 in Coventry, United Kingdom, with a goal to commercialise transdermal delivery platforms that broaden the applicability of transdermal administration for diverse medicines.

Optibrium is a software company that specializes in providing innovative solutions for small molecule design, optimization, and data analysis, aimed at enhancing the drug discovery process. Founded in 2009 and headquartered in Cambridge, UK, with an additional office in Boston, US, the company’s flagship product, StarDrop, is a comprehensive and user-friendly software suite that facilitates the integration of data, predictive modeling, and decision-making in research. This tool enables users to streamline their workflow from data analysis to compound synthesis, thereby increasing the speed and efficiency of drug discovery. Optibrium collaborates with a diverse range of clients, including leading pharmaceutical companies, biotech firms, and academic institutions, to continuously develop new technologies and improve productivity in drug development.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.